Trial results boost circulating tumor cell field.
نویسنده
چکیده
Tumor cells that invade the bloodstream and reach distant organs are the seeds of death. " Patients with cancer … don't die from the primary tumor, they always die from metastases, " said Leon Terstappen, M.D., Ph.D., chief scientific officer of Immunicon, a Pennsylvania biotechnology company. Because tumor cells make their way to the site of distant metastases via the bloodstream, " there must be cells there, " Terstappen pointed out. In theory, finding such circulating tumor cells, or CTCs, could identify metastatic disease at its very earliest stage. But the technical hurdles for creating such a clinical test are enormous. " We're looking for really one cell, a weird cell, in a background of maybe 20 million cells, " said David Krag, M.D., professor of surgery at the University of Vermont. " Boy, that can be really tough. " But research into circulating tumor cells took a big leap forward in June. In a talk at the American Society of Clinical Oncology (ASCO) annual meeting, University of Michigan medical oncolo-gist Dan Hayes, M.D., reported prospective clinical trial results using a test developed by Immunicon to detect CTCs in patients with metastatic breast cancer. Of 177 cancer patients, nearly 50% had at least five CTCs in a 7.5-milliliter blood sample before chemotherapy treatment, and 30% of these patients still exceeded this five-CTC threshold at a follow-up exam 3 to 4 weeks later. (No patients with benign conditions had more than two CTCs in a blood sample at any time.) Patients with a high CTC count had a much worse prognosis, but Hayes' most striking data showed that CTC count was associated with treatment response: for patients with five or more CTCs at first followup, progression-free survival was 2.1 months, compared with 7.0 months for patients with fewer than five CTCs. " These data suggest that, for a patient who has an elevated CTC level
منابع مشابه
Ultrasound-guided boost irradiation of tumor cavity after lumpectomy in breast cancer
Background: After breast conserving surgery, most recurrences occur around the primary tumor site. This justifies the use of boost radiotherapy to the primary site of tumor. Surgical scar is not always a good surrogate for the location of the lumpectomy cavity. The aim of this study was to evaluate ultrasonic guidance for detection of the lumpectomy cavity after breast conserving surgery ...
متن کاملCorrelation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study
Background: The analysis of the gene copy number alterations in tumor samples are increasingly used for diagnostic and prognostic purposes in patients with gastric cancer (GC). However, these procedures are not always applicable due to their invasive nature. In this study, we have analyzed the copy number alterations of five genes (HER2, MDM2, c-MYC, c-MET, and TP53) with a fixed relevance for ...
متن کاملCirculating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.
PURPOSE Circulating tumor cells in blood from metastatic breast cancer patients have been reported as a surrogate marker for tumor response and shorter survival. The aim of this study was to determine whether circulating tumor cells are present in the blood of patients with large operable or locally advanced breast cancer before neoadjuvant chemotherapy and after neoadjuvant chemotherapy before...
متن کاملAugmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a phase 1 clinical trial. Here, we report on the ability to boost immune responses with an additional dose of VGX-3100. Patients completing our initial phase 1 trial were offered enrollment into a follow on trial consisting of...
متن کاملClinical Trial of Prophylactic Extended-Field Carbon-Ion Radiotherapy for Locally Advanced Uterine Cervical Cancer (Protocol 0508)
UNLABELLED To evaluate the efficacy and the toxicity of prophylactic extended-field carbon-ion radiotherapy (C-ion RT, Protocol 0508) for locally advanced squamous cell carcinoma of the uterine cervix in phase I / II clinical trial. Between May 2006 and January 2012, 26 patients of Protocol 0508 were treated with C-ion RT. The numbers of patients with stage IIB, IIIB, and IVA disease were 13, 1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of the National Cancer Institute
دوره 96 14 شماره
صفحات -
تاریخ انتشار 2004